Charles Schwab
IDYA icon

Charles Schwab’s IDEAYA Biosciences IDYA Stock Holding History

Charles Schwab’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1M Buy
754,888
+39,361
+6% +$1.2M ﹤0.01% 1624
2026
Q1 		$23.8M Buy
715,527
+894
+0.1% +$30K ﹤0.01% 1643
2025
Q4 		$24.7M Sell
714,633
-905
-0.1% -$28.9K ﹤0.01% 1615
2025
Q3 		$19.5M Sell
715,538
-1,260
-0.2% -$30.5K ﹤0.01% 1754
2025
Q2 		$15.1M Buy
716,798
+13,082
+2% +$251K ﹤0.01% 1815
2025
Q1 		$11.5M Sell
703,716
-9,095
-1% -$194K ﹤0.01% 1887
2024
Q4 		$18.3M Buy
712,811
+23,738
+3% +$672K ﹤0.01% 1744
2024
Q3 		$21.8M Buy
689,073
+78,518
+13% +$2.98M ﹤0.01% 1649
2024
Q2 		$21.4M Buy
610,555
+40,966
+7% +$1.62M ﹤0.01% 1636
2024
Q1 		$25M Buy
569,589
+73,133
+15% +$3.14M 0.01% 1485
2023
Q4 		$17.7M Buy
496,456
+59,100
+14% +$1.76M ﹤0.01% 1671
2023
Q3 		$11.8M Buy
437,356
+291,240
+199% +$7.39M ﹤0.01% 1828
2023
Q2 		$3.43M Buy
146,116
+26,913
+23% +$553K ﹤0.01% 2377
2023
Q1 		$1.64M Buy
119,203
+1,065
+0.9% +$17.7K ﹤0.01% 2577
2022
Q4 		$2.15M Buy
118,138
+26,434
+29% +$445K ﹤0.01% 2550
2022
Q3 		$1.37M Buy
91,704
+885
+1% +$11.5K ﹤0.01% 2702
2022
Q2 		$1.25M Buy
90,819
+5,247
+6% +$58.4K ﹤0.01% 2711
2022
Q1 		$958K Buy
85,572
+2,109
+3% +$31.1K ﹤0.01% 2863
2021
Q4 		$1.97M Buy
83,463
+278
+0.3% +$6.46K ﹤0.01% 2711
2021
Q3 		$2.12M Buy
83,185
+17,549
+27% +$410K ﹤0.01% 2693
2021
Q2 		$1.38M Buy
65,636
+21,814
+50% +$448K ﹤0.01% 2826
2021
Q1 		$1.03M Buy
43,822
+4,614
+12% +$89.1K ﹤0.01% 2848
2020
Q4 		$549K Hold
39,208
– – ﹤0.01% 2957
2020
Q3 		$493K Buy
39,208
+13,285
+51% +$165K ﹤0.01% 2879
2020
Q2 		$369K Buy
+25,923
New +$204K ﹤0.01% 2955

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Charles Schwab's IDYA Position: Q2 2026 in Review

Charles Schwab increased its IDEAYA Biosciences (IDYA) stake by 5.5% in Q2 2026, buying an estimated $1.2M and bringing the position to 754,888 shares worth $28.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Charles Schwab first reported a position in IDYA in Q2 2020 and has held it in 25 quarters since. 284 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Charles Schwab held 754,888 shares of IDEAYA Biosciences worth $28.1M as of Q2 2026.
  • Charles Schwab bought 39,361 IDEAYA Biosciences shares in Q2 2026, an estimated $1.2M.
  • IDEAYA Biosciences made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1624 holding.
  • Charles Schwab first reported a position in IDEAYA Biosciences in Q2 2020 and has held it in 25 quarters since.
  • 284 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.